Certolizumab pegol in axial spondyloarthritis.

Item

http://www.wikidata.org/entity/Q38161555

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Certolizumab pegol in axial spondyloarthritis.

@en

type

Item

label

Certolizumab pegol in axial spondyloarthritis.

@en

prefLabel

Certolizumab pegol in axial spondyloarthritis.

@en

P1476

Certolizumab pegol in axial spondyloarthritis.

@en

P2093

In-Ho Song

http://www.w3.org/2001/XMLSchema#string

Martin Rudwaleit

http://www.w3.org/2001/XMLSchema#string

P2860

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol

Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48.

P304

1161-1172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/1744666X.2013.858859

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24215406

http://www.w3.org/2001/XMLSchema#string

Certolizumab pegol in axial spondyloarthritis.

about

P2860

P2860

Certolizumab pegol in axial spondyloarthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698